RESEARCH RECORD / GH-IGF-1 AXIS
Sermorelin research: what the GH/IGF-1 literature confirms, and where it stops.
The pediatric and aging endocrine findings, the pharmacokinetics, the cognition signal, and the limits of the adult anti-aging data — each datum logged to the study that measured it.
Before the details
Here is the research record in plain terms. Sermorelin makes the pituitary release the body's own growth hormone, and growth hormone in turn raises IGF-1, a hormone the liver makes. In children who were short because they lacked growth hormone, daily injections sped up growth. In older men, two weeks of injections pushed their growth-hormone and IGF-1 numbers back up toward young-adult levels. The peptide clears from the blood in about ten minutes, which is why longer-acting cousins were later designed. The weakest part of the record is long-term adult "anti-aging" use, where good evidence is thin.
How sermorelin works: the GHRH-receptor cascade
Sermorelin is the 1-29 fragment of GHRH and the shortest piece that retains full GHRH activity. It binds GHRH receptors on anterior-pituitary somatotrophs and activates the adenylate cyclase / cAMP / PKA pathway, stimulating GH gene transcription and pulsatile GH release. The signal is upstream: sermorelin tells the pituitary to act rather than supplying hormone directly, so somatostatin and IGF-1 negative feedback stay intact and the pulsatile pattern of secretion is preserved. A 2025 Nature Reviews Endocrinology review synthesizes the biology of GHRH and its analogues across health and disease, covering receptor signaling, the GH/IGF-1 axis, and the therapeutic uses of GHRH agonists and antagonists [15].
Does sermorelin work?
In the FDA-approved pediatric indication, yes — measurably. A multicenter trial of prepubertal GH-deficient children showed once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation [1]. In healthy older men, 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1, and after the high dose their GH/IGF-1 parameters no longer differed from young men's, with no change in fasting glucose [2]. Long-term adult anti-aging efficacy data, by contrast, remain limited [5].
Effects documented in the literature
The documented effects — not the marketed "benefits" — cluster on the GH/IGF-1 axis. Pediatric: accelerated linear growth in GH-deficient children [1], and sustained growth over two years in a subset of significantly short children with normal GH given 30 mcg/kg/day [8]. Aging endocrinology: reversal of age-related declines in 24-hour GH and IGF-1 in older men [2]. Diagnostics: a single intravenous GRF(1-29)NH2 bolus separated GH-deficient from normal children — normal-stature children peaked at a mean plasma GH of 80.31 ng/ml versus 13.10 ng/ml in GH-deficient children [11]. These are endpoints measured in trials, not cosmetic outcomes; the anti-aging and body-composition marketing outpaces the evidence [5].
Half-life and pharmacokinetics
Sermorelin's plasma half-life is short — on the order of ~10-12 minutes after intravenous administration. Despite that rapid clearance, a single dose elevates serum GH for roughly 3 hours [3]. Intravenous doses of 0.25-2 mcg/kg elicited dose-dependent GH release in healthy men, while intranasal bioavailability was only ~3-5% [3]. That brevity is the engineering problem the field set out to solve: the native peptide's short duration motivated longer-acting analogs built with a D-Ala2 substitution and with DAC (Drug Affinity Complex) albumin-binding technology. How sermorelin compares to CJC-1295 covers those modifications.
Subcutaneous injection in the studies
Subcutaneous injection was the primary studied route. The pediatric efficacy trial dosed once daily subcutaneously at bedtime [1]; the older-men study used subcutaneous twice-daily dosing for 14 days [2]. Intravenous dosing appears in pharmacokinetic and diagnostic work [3][11], and an intranasal form was tried historically but performed poorly — a 6-month pilot in eight short children given intranasal GHRH(1-29)NH2 at 50 mcg/kg three times daily saw GH peak amplitudes decline, antibodies appear in three patients by 6 weeks, and no increase in height velocity, leading the authors to call intranasal GHRH in that form unsuitable for children [7].
What studies report before and after sermorelin treatment
"Before and after" in this literature means measured endpoints, not cosmetic photos. Before/after in GH-deficient children: first-year height velocity rose from about 4.1 to roughly 7-8 cm/year on once-daily subcutaneous GHRH(1-29) [1]. Before/after in older men: 14 days of subcutaneous GHRH(1-29) moved 24-hour GH and IGF-1 from age-suppressed values to levels indistinguishable from young men's at the high dose [2]. In short children with normal GH, evening subcutaneous GRF(1-29)NH2 at 5 mcg/kg increased growth velocity over 6 months even though 24-hour GH profiles were unchanged [10]. The honest gap is that comparable controlled before/after data for general adult anti-aging use do not exist [5].
Reported side effects and the limits of long-term data
Across studies, reported effects of GHRH(1-29) have generally been mild — most commonly local injection-site reactions. The randomized older-adult cognition trial reported mild adverse events [6]. The principal caveats are about what is not yet known and one mechanistic concern. Long-term tolerability data for adult anti-aging use are limited, and an Annals of Internal Medicine editorial called GH-secretagogue anti-aging use "not yet ready for prime time" [5]. Because GH and IGF-1 are mitogenic (growth-promoting at the cellular level), chronically raising them is a recognized theoretical oncologic-risk consideration for any GH-axis intervention — even one that, like sermorelin, works through the body's own feedback-regulated secretion. This page describes findings; it is not a dosing recommendation.
Sermorelin and sleep
GHRH has documented sleep-promoting effects in research: it increased slow-wave sleep in normal men, and its sleep-endocrine effects depend on the timing of administration. The connection runs both ways — GH is secreted largely during early slow-wave sleep, which is part of the rationale behind bedtime dosing in studies [1]. A clinical study of single nightly subcutaneous GHRH(1-29) injections in healthy elderly men examined exactly whether bedtime dosing could restore nocturnal GH output in aging [14].
Sermorelin and body fat
Direct sermorelin fat-loss trials are limited. The body-composition signal in the literature comes largely from the related stabilized GHRH analog tesamorelin, which significantly reduced visceral adipose tissue versus placebo in HIV-associated fat accumulation; pulsatile GH itself contributes to lipolysis. In the older-adult cognition trial, the daily GHRH analog (tesamorelin) reduced percent body fat by 7.4% [6]. This is GHRH-axis and drug-class evidence — not a sermorelin-specific cosmetic claim. There is no robust sermorelin weight-loss trial, and anti-aging/weight marketing outpaces the evidence [5].
Is sermorelin effective for weight loss?
There is no robust sermorelin weight-loss trial evidence. The body-composition data in this literature are from tesamorelin's effect on visceral fat in specific clinical populations and from GH's general role in lipolysis [6] — not a demonstrated general weight-loss effect of sermorelin. Treating that drug-class signal as a sermorelin weight-loss claim is exactly the kind of single-finding extrapolation the evidence does not support [5].
Sermorelin and testosterone
Sermorelin acts on the GH/IGF-1 axis, a separate hormonal pathway from the hypothalamic-pituitary-gonadal axis that governs testosterone. The men's-health literature frames GH secretagogues around raising IGF-1 and shifting body composition [2], not around directly altering testosterone. No testosterone-altering effect of sermorelin is established in this record.
Does sermorelin raise IGF-1?
Yes. By stimulating GH release, sermorelin drives hepatic IGF-1 production. In older men, 14 days of subcutaneous GHRH(1-29) produced dose-related IGF-1 increases that, at the high dose, brought GH/IGF-1 levels in line with those of young men — all within the physiologic range [2]. In the older-adult cognition trial, the GHRH analog raised IGF-1 by 117%, also within the physiologic range [6].
Does sermorelin build muscle?
There is no direct sermorelin muscle-hypertrophy trial in this literature. The mechanistic rationale is the GH/IGF-1 axis, and reviews discuss GH/IGF-1 modulation as a candidate strategy against age-related muscle loss (sarcopenia) [15] — a hypothesis-level framing, not demonstrated muscle-building in healthy adults. The honest status is "plausible mechanism, no direct evidence."
Sermorelin and the brain
GHRH administration has measurable neuroendocrine effects. In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a daily subcutaneous GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition (P=0.03; executive function P=0.005), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%, with mild adverse events [6]. A related study found GHRH altered brain GABA levels in mild cognitive impairment and healthy aging.
Can GHRH improve cognition in older adults?
In the controlled 152-participant trial above, 20 weeks of a daily subcutaneous GHRH analog had a favorable effect on cognition, raised IGF-1 by 117%, and reduced percent body fat by 7.4%, with mild adverse events [6]. The result is for a GHRH analog (tesamorelin) and is a single controlled trial — encouraging and specific, but not by itself a settled clinical indication for sermorelin.
Frontier research on GHRH analogs
Beyond the GH/IGF-1 axis, GHRH-receptor agonist analogs have been explored preclinically. One study described a therapeutic approach to heart failure after myocardial infarction based on targeting the GHRH receptor, improving post-infarction cardiac outcomes in the model [12]. A computational drug-repurposing screen has also flagged a sermorelin signal in glioma. These are hypothesis-generating preclinical and in-silico findings — not evidence that sermorelin treats those conditions. (Analytical chemistry has kept pace: GHRH analogs in human plasma can be confirmed by immunoaffinity purification plus LC-HRMS/MS [13], the basis for anti-doping detection.)